The synthetic biopsy method is designed to improve the sensitivity and specificity of cancer detection. Credit: Chinnapong/Shutterstock.

Accenture has invested in biotechnology company Earli to advance early cancer detection technologies.

Facilitated through Accenture Ventures, the investment aims to enhance collaborations with global health and pharma companies, leveraging Earli’s synthetic targeting platform that reprogrammes cancer cells to aid in their detection and destruction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Earli’s technology focuses on the early and accurate distinction between healthy and cancerous cells.

The synthetic biopsy method is designed to improve the sensitivity and specificity of cancer detection, potentially leading to earlier diagnoses and more personalised treatment options.

Earli’s technology is poised to revolutionise cancer detection by using non-invasive screening methods, such as blood samples and PET [positron emission topography] scans, to identify multiple cancer types.

See Also:

The investment from Accenture Ventures is expected to help Earli expand its collaborations, potentially accelerating the development and availability of early cancer detection and treatment solutions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earli joins Accenture Ventures’ engagement and investment programme, Project Spotlight, working with startups on disruptive enterprise technologies.

Accenture Life Sciences business senior managing director and global lead Petra Jantzer stated: “Earli’s synthetic biopsy method is a step change in early cancer detection technologies and will offer significant advantages to biopharma companies by improving the precision and efficacy of new treatments and diagnostics, as well as in understanding the mechanisms of cancer progressions.”

Project Spotlight provides access to the domain expertise of Accenture as well as its enterprise clients.

Biotechnology companies Turbine, QuantHealth, Virtonomy and Ocean Genomics have also joined Project Spotlight.

Accenture Ventures global lead Tom Lounibos said: “With Earli joining our Project Spotlight programme, we can collaborate with our clients in the biopharma industry to advance their capabilities in cancer research, drug development and patient care.”